Skip to content
Menu

ProMIS Neurosciences, Inc. PMN

Full chart Compare
Set alert

Price alert · PMN

All alert types
3.21 USD +0.08 (+2.56%)

Regular-session close

3.17 -0.04 -1.25%

After hours · Nov 19, 4:37 PM ET

3.02 Day range 3.45
2.78 52-week range 27.40
YTD
-53.00%
1 year
-69.43%

5D -1.01 (-23.93%)

33.504WedThuFriMonTue3.21
Market cap
28.88M
EPS (ttm)
-6.50
Shares out
32.69M
Forward P/E
-1.51
YTD return
-53.00%
1-year return
-69.43%
50-day average
0.9886
200-day average
1.51
Enterprise value
28.70M
Volume
172.34K
Avg volume
160.88K
Open
3.39
Previous close
3.13
Day's range
3.02 – 3.45
52-week range
2.78 – 27.40
Beta
0.61
Analysts
Strong Buy
Price target
7.65 (+138.3%)

Key statistics

Price / book
4.62
Free cash flow
-12.77M
Total cash
1.02M
Short % of float
1.04%

Fundamental scorecard

6 of 25 checks passed on PMN’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PMN Revenue — quarterly 0
PMN Net income — quarterly -8.16M
PMN EPS — quarterly -0.89

Earnings

PMN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.14——
Aug 8, 2024Jun 1, 20240.00———
Aug 8, 2024Jun 1, 20240.00-0.13——
May 14, 2024Mar 1, 20240.00-0.19——
May 14, 2024Mar 1, 20240.00———
Apr 1, 2024Dec 1, 20230.00———

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada

News

Your note

Sign in to keep a note on PMN — it syncs with the Stock Master app.

Insider holders

PMN insider holders
InsiderRelationLatest transactionDateShares held
CASHMAN NEILOfficer and DirectorStock Award(Grant)Aug 22, 2023114,921
FARFEL GAIL MChief Executive OfficerStock Award(Grant)Aug 22, 202355,192
GORDON MICHAEL STEPHENBeneficial Owner of more than 10% of a Class of SecurityPurchaseSep 16, 20242,217,180
KIRWIN PATRICK DDirectorPurchaseAug 13, 202499,096
MALENFANT GAVIN T.Chief Operating OfficerStock Award(Grant)Aug 22, 20232,660
MILBURY MAX A.OfficerStock Award(Grant)Aug 22, 202314,997

Institution ownership

PMN institution ownership
Holder% heldSharesValueReported
Great Point Partners LLC8.54%2,790,6982.57MSep 29, 2024
Armistice Capital, LLC8.17%2,670,0002.46MSep 29, 2024
Sphera Funds Management Ltd.5.90%1,929,2971.77MSep 29, 2024
Ally Bridge Group (NY) LLC4.87%1,592,6051.47MSep 29, 2024
Altium Capital Management, LP1.78%581,395534.88KSep 29, 2024
Heights Capital Management, Inc 1.18%386,894355.94KSep 29, 2024

Fund ownership

PMN fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.03%8,6227.93KOct 30, 2024